Chengda Biotech: Freeze-dried human rabies vaccine obtains drug registration certificate.

Chengda Bio announced that its wholly-owned subsidiary, Chengda Bio Limited, has received the Drug Registration Certificate for freeze-dried human rabies vaccine issued by the National Medical Products Administration. The vaccine uses the human diploid cell MRC-5 recommended by the World Health Organization as the cell matrix, with excellent safety, immunogenicity and immunogenic persistence, especially suitable for immunocompromised populations such as those with allergies, the elderly, and children. This product is the first in China to cover three immunization programs for human diploid cell rabies vaccine: "Simple 4-dose regimen," "2-1-1 regimen," and "5-dose regimen." The approval of the "Simple 4-dose regimen" immunization program marks a new breakthrough in the adaptability of the human diploid cell rabies vaccine immunization program in China.